Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PRLD Prelude Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: PRLD
Price (delayed)
$0.8832
Market cap
$49.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.69
Enterprise value
$23.47M
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective
Highlights
The EPS has increased by 10% year-on-year
The quick ratio has plunged by 55% YoY and by 3% from the previous quarter
The equity has dropped by 51% year-on-year and by 22% since the previous quarter
Key stats
What are the main financial stats of PRLD
Market
Valuations
Earnings
Shares outstanding
56.46M
Market cap
$49.87M
Enterprise value
$23.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$146.98M
Net income
-$127.83M
EBIT
-$127.83M
EBITDA
-$124.49M
Free cash flow
-$105.85M
Per share
Balance sheet
Liquidity
EPS
-$1.69
EPS diluted
-$1.69
Free cash flow per share
-$1.39
Book value per share
$1.87
Revenue per share
$0
TBVPS
$1.86
Total assets
$141.26M
Total liabilities
$38.08M
Debt
$17.92M
Equity
$103.18M
Working capital
$82.62M
Debt to equity
0.17
Current ratio
5.18
Quick ratio
5.21
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-69.3%
Return on equity
-89.2%
Return on invested capital
-83.6%
Return on capital employed
-105.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRLD stock price
How has the Prelude Therapeutics stock price performed over time
Intraday
-5.74%
1 week
13.09%
1 month
14.7%
1 year
-79.36%
YTD
-30.73%
QTD
15%
Financial performance
How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$146.98M
Net income
-$127.83M
Gross margin
N/A
Net margin
N/A
PRLD's operating income is down by 7% year-on-year
Price vs fundamentals
How does PRLD's price correlate with its fundamentals
Growth
What is Prelude Therapeutics's growth rate over time
Valuation
What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
0.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 10% year-on-year
The stock's P/B is 82% below its 5-year quarterly average of 2.6 and 33% below its last 4 quarters average of 0.7
The equity has dropped by 51% year-on-year and by 22% since the previous quarter
Efficiency
How efficient is Prelude Therapeutics business performance
PRLD's return on equity has dropped by 68% year-on-year and by 19% since the previous quarter
Prelude Therapeutics's ROIC has plunged by 53% YoY and by 21% from the previous quarter
The ROA has contracted by 47% YoY and by 15% from the previous quarter
Dividends
What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRLD.
Financial health
How did Prelude Therapeutics financials performed over time
The current ratio has dropped by 55% year-on-year and by 2.3% since the previous quarter
The quick ratio has plunged by 55% YoY and by 3% from the previous quarter
The debt is 83% lower than the equity
PRLD's debt to equity has surged by 113% year-on-year and by 21% since the previous quarter
The equity has dropped by 51% year-on-year and by 22% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.